{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:57Z","timestamp":1792197297614,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7607","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/nature18288","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T11:43:07Z","timestamp":1465299787000},"page":"341-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":208,"title":["Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells"],"prefix":"10.1038","volume":"534","author":[{"given":"Sheela A.","family":"Abraham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E. M.","family":"Hopcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Carrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Drotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J. K.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koorosh","family":"Korfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pellicano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Nourse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Grimmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vetrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Whetton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,8]]},"reference":[{"key":"BFnature18288_CR1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare, T., Zabriskie, M. S., Eiring, A. M. & Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature Rev. Cancer 12, 513\u2013526 (2012)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature18288_CR2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038\u20131042 (2001)","journal-title":"N. Engl. J. Med."},{"key":"BFnature18288_CR3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319\u2013325 (2002)","journal-title":"Blood"},{"key":"BFnature18288_CR4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010)","journal-title":"Lancet Oncol."},{"key":"BFnature18288_CR5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A. S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396\u2013409 (2011)","journal-title":"J. Clin. Invest."},{"key":"BFnature18288_CR6","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","volume":"123","author":"P Neviani","year":"2013","unstructured":"Neviani, P. et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J. Clin. Invest. 123, 4144\u20134157 (2013)","journal-title":"J. Clin. Invest."},{"key":"BFnature18288_CR7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF01386390","volume":"1","author":"EW Dijkstra","year":"1959","unstructured":"Dijkstra, E. W. A note on two problems in connexion with graphs. Numer. Math. 1, 269\u2013271 (1959)","journal-title":"Numer. Math."},{"key":"BFnature18288_CR8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/1947601910379011","volume":"1","author":"C Van Dang","year":"2010","unstructured":"Van Dang, C. & McMahon, S. B. Emerging concepts in the analysis of transcriptional targets of the MYC oncoprotein: are the targets targetable? Genes Cancer 1, 560\u2013567 (2010)","journal-title":"Genes Cancer"},{"key":"BFnature18288_CR9","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1021\/pr500601w","volume":"13","author":"AP Boichenko","year":"2014","unstructured":"Boichenko, A. P. et al. A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer. J. Proteome Res. 13, 4995\u20135007 (2014)","journal-title":"J. Proteome Res."},{"key":"BFnature18288_CR10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1074\/mcp.M114.038273","volume":"13","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol. Cell. Proteomics 13, 1753\u20131768 (2014)","journal-title":"Mol. Cell. Proteomics"},{"key":"BFnature18288_CR11","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/pr100113a","volume":"9","author":"CW Sutton","year":"2010","unstructured":"Sutton, C. W. et al. Quantitative proteomic profiling of matched normal and tumor breast tissues. J. Proteome Res. 9, 3891\u20133902 (2010)","journal-title":"J. Proteome Res."},{"key":"BFnature18288_CR12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1074\/mcp.M700251-MCP200","volume":"7","author":"A Pierce","year":"2008","unstructured":"Pierce, A. et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol. Cell. Proteomics 7, 853\u2013863 (2008)","journal-title":"Mol. Cell. Proteomics"},{"key":"BFnature18288_CR13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","volume":"10","author":"N Issaeva","year":"2004","unstructured":"Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53\u2013HDM-2 interaction and activates p53 function in tumors. Nature Med. 10, 1321\u20131328 (2004)","journal-title":"Nature Med."},{"key":"BFnature18288_CR14","doi-asserted-by":"crossref","first-page":"e1450","DOI":"10.1038\/cddis.2014.396","volume":"5","author":"C Wong","year":"2014","unstructured":"Wong, C. et al. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis. 5, e1450 (2014)","journal-title":"Cell Death Dis."},{"key":"BFnature18288_CR15","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669\u201316674 (2011)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature18288_CR16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501\u20131510 (2012)","journal-title":"Blood"},{"key":"BFnature18288_CR17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","volume":"21","author":"L Li","year":"2012","unstructured":"Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266\u2013281 (2012)","journal-title":"Cancer Cell"},{"key":"BFnature18288_CR18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","volume":"14","author":"NP Shah","year":"2008","unstructured":"Shah, N. P. et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485\u2013493 (2008)","journal-title":"Cancer Cell"},{"key":"BFnature18288_CR19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010)","journal-title":"Cancer Res."},{"key":"BFnature18288_CR20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","volume":"107","author":"AS Yong","year":"2006","unstructured":"Yong, A. S., Szydlo, R. M., Goldman, J. M., Apperley, J. F. & Melo, J. V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107, 205\u2013212 (2006)","journal-title":"Blood"},{"key":"BFnature18288_CR21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","volume":"115","author":"SK McWeeney","year":"2010","unstructured":"McWeeney, S. K. et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 115, 315\u2013325 (2010)","journal-title":"Blood"},{"key":"BFnature18288_CR22","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-12-2807","volume":"73","author":"C Tovar","year":"2013","unstructured":"Tovar, C. et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 73, 2587\u20132597 (2013)","journal-title":"Cancer Res."},{"key":"BFnature18288_CR23","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","volume":"59","author":"BK Albrecht","year":"2016","unstructured":"Albrecht, B. K. et al. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials. J. Med. Chem. 59, 1330\u20131339 (2016)","journal-title":"J. Med. Chem."},{"key":"BFnature18288_CR24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","volume":"17","author":"B Zhang","year":"2010","unstructured":"Zhang, B. et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427\u2013442 (2010)","journal-title":"Cancer Cell"},{"key":"BFnature18288_CR25","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","volume":"208","author":"C Hurtz","year":"2011","unstructured":"Hurtz, C. et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 208, 2163\u20132174 (2011)","journal-title":"J. Exp. Med."},{"key":"BFnature18288_CR26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/stem.5530130416","volume":"13","author":"F Lanza","year":"1995","unstructured":"Lanza, F. & Bi, S. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells 13, 445\u2013452 (1995)","journal-title":"Stem Cells"},{"key":"BFnature18288_CR27","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2012.246","volume":"32","author":"MT G\u00f3mez-Casares","year":"2013","unstructured":"G\u00f3mez-Casares, M. T. et al. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1). Oncogene 32, 2239\u20132246 (2013)","journal-title":"Oncogene"},{"key":"BFnature18288_CR28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nchembio.1085","volume":"8","author":"GE Winter","year":"2012","unstructured":"Winter, G. E. et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chem. Biol. 8, 905\u2013912 (2012)","journal-title":"Nature Chem. Biol."},{"key":"BFnature18288_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2013.01.026","volume":"23","author":"S Takeishi","year":"2013","unstructured":"Takeishi, S. et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23, 347\u2013361 (2013)","journal-title":"Cancer Cell"},{"key":"BFnature18288_CR30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","volume":"23","author":"L Reavie","year":"2013","unstructured":"Reavie, L. et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 23, 362\u2013375 (2013)","journal-title":"Cancer Cell"},{"key":"BFnature18288_CR31","first-page":"a014217","volume":"3","author":"CVMYC Dang","year":"2013","unstructured":"Dang, C. V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med. 3, a014217 (2013)","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"BFnature18288_CR32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413\u2013431 (2009)","journal-title":"Cell"},{"key":"BFnature18288_CR33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Rev. Cancer 13, 83\u201396 (2013)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature18288_CR34","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1128\/MCB.05672-11","volume":"32","author":"H Zhang","year":"2012","unstructured":"Zhang, H., Li, H., Ho, N., Li, D. & Li, S. Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia. Mol. Cell. Biol. 32, 1776\u20131787 (2012)","journal-title":"Mol. Cell. Biol."},{"key":"BFnature18288_CR35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature14985","volume":"525","author":"TY Hsu","year":"2015","unstructured":"Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384\u2013388 (2015)","journal-title":"Nature"},{"key":"BFnature18288_CR36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature14351","volume":"523","author":"CM Koh","year":"2015","unstructured":"Koh, C. M. et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523, 96\u2013100 (2015)","journal-title":"Nature"},{"key":"BFnature18288_CR37","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538\u2013542 (2015)","journal-title":"Nature"},{"key":"BFnature18288_CR38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost, S. et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature 525, 380\u2013383 (2015)","journal-title":"Nature"},{"key":"BFnature18288_CR39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bbapap.2006.02.004","volume":"1764","author":"L Pizzatti","year":"2006","unstructured":"Pizzatti, L., S\u00e1, L. A., de Souza, J. M., Bisch, P. M. & Abdelhay, E. Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study. Biochim. Biophys. Acta 1764, 929\u2013942 (2006)","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnature18288_CR40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","volume":"122","author":"K Cramer-Morales","year":"2013","unstructured":"Cramer-Morales, K. et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 122, 1293\u20131304 (2013)","journal-title":"Blood"},{"key":"BFnature18288_CR41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.leu.2404549","volume":"21","author":"E Diaz-Blanco","year":"2007","unstructured":"Diaz-Blanco, E. et al. Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21, 494\u2013504 (2007)","journal-title":"Leukemia"},{"key":"BFnature18288_CR42","doi-asserted-by":"crossref","first-page":"798592","DOI":"10.1155\/2011\/798592","volume":"2011","author":"M Affer","year":"2011","unstructured":"Affer, M. et al. Gene expression differences between enriched normal and chronic myelogenous leukemia quiescent stem\/progenitor cells and correlations with biological abnormalities. J. Oncol. 2011, 798592 (2011)","journal-title":"J. Oncol."},{"key":"BFnature18288_CR43","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1634\/stemcells.2007-0250","volume":"25","author":"SM Graham","year":"2007","unstructured":"Graham, S. M., Vass, J. K., Holyoake, T. L. & Graham, G. J. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25, 3111\u20133120 (2007)","journal-title":"Stem Cells"},{"key":"BFnature18288_CR44","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/bioinformatics\/18.suppl_1.S96","volume":"18","author":"W Huber","year":"2002","unstructured":"Huber, W., von Heydebreck, A., S\u00fcltmann, H., Poustka, A. & Vingron, M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 (suppl. 1), S96\u2013S104 (2002)","journal-title":"Bioinformatics"},{"key":"BFnature18288_CR45","unstructured":"Smyth, G. K. in Bioinformatics and Computational Biology Solutions using R and Bioconductor (eds Gentleman, R., Dudoit, S., Irizarry, R. & Huber, W. ) 397\u2013420 (Springer, 2005)"},{"key":"BFnature18288_CR46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289\u2013300 (1995)","journal-title":"J. R. Stat. Soc. B"},{"key":"BFnature18288_CR47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007)","journal-title":"Biostatistics"},{"key":"BFnature18288_CR48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013)","journal-title":"BMC Bioinformatics"},{"key":"BFnature18288_CR49","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2202\/1544-6115.1027","volume":"3","author":"GK Smyth","year":"2004","unstructured":"Smyth, G. K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, e3 (2004)","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"key":"BFnature18288_CR50","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1088821","volume":"302","author":"AG Clark","year":"2003","unstructured":"Clark, A. G. et al. Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios. Science 302, 1960\u20131963 (2003)","journal-title":"Science"},{"key":"BFnature18288_CR51","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.cell.2009.03.051","volume":"137","author":"XL Xu","year":"2009","unstructured":"Xu, X. L. et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 137, 1018\u20131031 (2009)","journal-title":"Cell"},{"key":"BFnature18288_CR52","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1073\/pnas.0914203107","volume":"107","author":"A Wolfer","year":"2010","unstructured":"Wolfer, A. et al. MYC regulation of a \u201cpoor-prognosis\u201d metastatic cancer cell state. Proc. Natl Acad. Sci. USA 107, 3698\u20133703 (2010)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature18288_CR53","doi-asserted-by":"crossref","first-page":"e1152","DOI":"10.1038\/cddis.2014.112","volume":"5","author":"A Sheth","year":"2014","unstructured":"Sheth, A. et al. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis. 5, e1152 (2014)","journal-title":"Cell Death Dis."},{"key":"BFnature18288_CR54","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013)","journal-title":"Nucleic Acids Res."},{"key":"BFnature18288_CR55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014)","journal-title":"Bioinformatics"},{"key":"BFnature18288_CR56","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010)","journal-title":"Genome Biol."},{"key":"BFnature18288_CR57","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014)","journal-title":"Genome Biol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature18288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature18288","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature18288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:53:08Z","timestamp":1718610788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature18288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":57,"journal-issue":{"issue":"7607","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFnature18288"],"URL":"https:\/\/doi.org\/10.1038\/nature18288","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726403458.793520793","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"8 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}